Varlilumab - Celldex Therapeutics

Drug Profile

Varlilumab - Celldex Therapeutics

Alternative Names: CDX-1127

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours
  • Phase I/II Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Phase I Glioma
  • No development reported Haematological malignancies; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 02 Jun 2018 Updated efficacy data from a phase I/II trial in Solid tumours presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2018)
  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
  • 07 Mar 2018 Celldex therapeutics has patent protection for varlilumab in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top